Drug Trial Radar · NCT03256422
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
Last checked: Nov 20, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
640
Actual
Start
Sep 7, 2017
Primary completion
Aug 6, 2019
Study completion Mar 2, 2020
Sponsor
- Lead sponsor
- ANRS, Emerging Infectious DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba; Institut National de la Santé Et de la Recherche Médicale, France
- First posted
- Aug 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial is an open-label, multicenter, prospective, randomized trial in 2 parallel groups, evaluating at W48, the non-inferiority of antiretroviral treatment taken 4 consecutive days a week versus continuous therapy, in HIV infected patients with controlled viral load for at least 12 months and stable antiretroviral treatment since 4 months.
Conditions
- HIV Infections
Interventions
Treatment discontinuationDrug
• Receiving tritherapy. Allowed treatment drugs are : 1. nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine 2. protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r 3. non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine 4. integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with therapeutic success at Week 48.Time frame: Week 48
Locations
63 sites in 1 country. Site status is shown where the registry gives one.
Centre hospitalier Victor Dupouy
Argenteuil, France
Hôpital Henri Duffaut
Avignon, France
CHRU Jean Minjoz
Besançon, France
Avicenne
Bobigny, France
Jean Verdier
Bondy, France
Hôpital Saint-André
Bordeaux, France
Hôpital Pellegrin
Bordeaux, France
Hôpital Ambroise Paré
Boulogne-Billancourt, France
Hôpital de la Côte de Nacre
Caen, France
Hôpital Louis Pasteur
Chartres, France
Antoine Beclère
Clamart, France
Hôpital Gabriel Montpied
Clermont-Ferrand, France
Centre hospitalier sud francilien
Corbeil-Essonnes, France
CHI de Créteil
Créteil, France
Hôpital Henri Mondor
Créteil, France
Hôpital du Bocage
Dijon, France
Hôpital Raymond Poincaré
Garches, France
Hôpital Michallon
Grenoble, France
CHD de la Roche Sur Yon
La Roche-sur-Yon, France
Bicêtre
Le Kremlin-Bicêtre, France
Centre Hospitalier du Mans
Le Mans, France
Institut hospitalier franco-britannique
Levallois-Perret, France
Hôpital Dupuytren
Limoges, France
Hôpital de la Croix Rousse
Lyon, France
Hôpital Edouard Herriot
Lyon, France
Hôpital Sainte Marguerite
Marseille, France
Hôpital Européen
Marseille, France
Hôpital Gui de Chauliac
Montpellier, France
Hôpital Emile Müller
Mulhouse, France
Hôpital de l'Hôtel Dieu
Nantes, France
Hôpital de l'Archet
Nice, France
Hôpital Carémeau
Nîmes, France
Hôpital de La Source
Orléans, France
Hôpital Saint-Antoine
Paris, France
Hôpital Necker
Paris, France
Hôpital Bichat
Paris, France
Hôpital de l'Hôtel Dieu
Paris, France
Hôtel-Dieu
Paris, France
Hôpital Saint-Louis
Paris, France
Lariboisière
Paris, France
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.